At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
In Brief
A Phase 2 clinical trial evaluating Modified Vaccinia Virus Ankara Vaccine Expressing p53 and Pembrolizumab for Recurrent Platinum-Resistant Fallopian Tube Carcinoma and 2 related conditions. Active but no longer recruiting, targeting 29 participants across 1 site.
Detailed Summary
This phase II trial studies how well modified vaccinia virus ankara vaccine expressing p53 (p53MVA) and pembrolizumab work in treating patients with ovarian, primary peritoneal, or fallopian tube cancer that has come back (recurrent). Vaccines made from a gene-modified virus may help the body build an effective immune response to kill tumor cells. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving p53MVA and pembrolizumab together may work better in treating patients with ovarian, primary peritoneal, or fallopian tube cancer.
Study Details
Timeline
Interventions
Given SC
Given IV